Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the ...
Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, ...
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success ...
Eli Lilly built up $1.5 billion in pre-launch inventory for its experimental oral weight-loss drug orforglipron, according to a regulatory filing.
The EY deals leader discusses recent findings and trends from 2025.
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, discusses how Soley uses human cells to guide drug discovery, ...
After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation ...
In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum ...
Novo Nordisk, the manufacturer of Wegovy, responded strongly to the initial launch of Hims & Hers’ compounded semaglutide ...
FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results